Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics

被引:32
作者
Caro, J. Jaime [1 ,2 ,3 ]
机构
[1] McGill Univ, Montreal, PQ, Canada
[2] Evidera, Boston, MA USA
[3] 39 Bypass Rd, Lincoln, MA 01773 USA
关键词
ECONOMIC-EVALUATION; MODEL;
D O I
10.1007/s40273-016-0394-z
中图分类号
F [经济];
学科分类号
02 ;
摘要
Several decision-analytic modeling techniques are in use for pharmacoeconomic analyses. Discretely integrated condition event (DICE) simulation is proposed as a unifying approach that has been deliberately designed to meet the modeling requirements in a straightforward transparent way, without forcing assumptions (e.g., only one transition per cycle) or unnecessary complexity. At the core of DICE are conditions that represent aspects that persist over time. They have levels that can change and many may coexist. Events reflect instantaneous occurrences that may modify some conditions or the timing of other events. The conditions are discretely integrated with events by updating their levels at those times. Profiles of determinant values allow for differences among patients in the predictors of the disease course. Any number of valuations (e.g., utility, cost, willingness-to-pay) of conditions and events can be applied concurrently in a single run. A DICE model is conveniently specified in a series of tables that follow a consistent format and the simulation can be implemented fully in MS Excel, facilitating review and validation. DICE incorporates both state-transition (Markov) models and non-resource-constrained discrete event simulation in a single formulation; it can be executed as a cohort or a microsimulation; and deterministically or stochastically.
引用
收藏
页码:665 / 672
页数:8
相关论文
共 19 条
  • [1] Berg BA, 2005, LECT NOTES SER INST, V7, P1
  • [2] A taxonomy of model structures for economic evaluation of health technologies
    Brennan, Alan
    Chick, Stephen E.
    Davies, Ruth
    [J]. HEALTH ECONOMICS, 2006, 15 (12) : 1295 - 1310
  • [3] Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
    Briggs, Andrew H.
    Weinstein, Milton C.
    Fenwick, Elisabeth A. L.
    Karnon, Jonathan
    Sculpher, Mark J.
    Paltiel, A. David
    [J]. VALUE IN HEALTH, 2012, 15 (06) : 835 - 842
  • [4] Caro JJ., 2015, DISCRETE EVENT SIMUL
  • [5] Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
    Eddy, David M.
    Hollingworth, William
    Caro, J. Jaime
    Tsevat, Joel
    McDonald, Kathryn M.
    Wong, John B.
    [J]. VALUE IN HEALTH, 2012, 15 (06) : 843 - 850
  • [6] Goldsman D, 2010, P 2010 WINT SIM C
  • [7] Howard RA., FDN DECISION ANAL RE
  • [8] The decision rules of cost-effectiveness analysis
    Karlsson, G
    Johannesson, M
    [J]. PHARMACOECONOMICS, 1996, 9 (02) : 113 - 120
  • [9] Recent advances in the methods of cost-benefit analysis in healthcare - Matching the art to the science
    McIntosh, E
    Donaldson, C
    Ryan, M
    [J]. PHARMACOECONOMICS, 1999, 15 (04) : 357 - 367
  • [10] EQUATION OF STATE CALCULATIONS BY FAST COMPUTING MACHINES
    METROPOLIS, N
    ROSENBLUTH, AW
    ROSENBLUTH, MN
    TELLER, AH
    TELLER, E
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1953, 21 (06) : 1087 - 1092